- What have Member States done to harmonise procedures
- Templates and Procedures developed e.g pre-CTA
- FAST EU and Fast track for early phases
Archives: Agenda
End of Conference
Lunch and networking
Lunch and networking
Beyond RBQM: How Intelligent RBQM Gives Sponsors and CROs a Measurable Edge
Most Sponsors and CROs have made the move to RBQM at an operational level – but is the approach actually intelligent, or is it still driven by manual review cycles, static risk thresholds and teams buried in reporting?
- Moving from operational RBQM to AI-enabled RBQM that learns, adapts and surfaces the right signals before they become issues
- Identifying where operational RBQM is still leaving value on the table and where AI can create a step change in quality and efficiency
- Examining what the data shows about improvements in speed, accuracy and cost
- Achieving real-time inspection readiness for Sponsors and building a quality capability that helps CROs win and retain business
Afternoon refreshments, networking & Prize Draw
Implementing the New UK Clinical Trial Regulation: What Sponsors Need to Do Differently
- Understanding how the new UK framework is working in practice 6 months after implementation
- Identifying key operational changes, including approvals, consent, and trial setup
- Clarifying how sponsors can take advantage of faster pathways while staying compliant
PANEL DISCUSSION: Debating Ownership and Risk Sharing in Sponsor and Vendor Partnerships
- Exploring the meaning of risk sharing across roles
- Supporting balance between procurement and R&D priorities
- Strengthening partnership models through transparency
Moderator
Alexander Booth, Host, Lab to Lives Podcast
STANDUP COMEDY: Taking a light-hearted look at the realities of working in clinical trials and life sciences
Maintaining Control While Working with CROs and Improving Oversight Without Slowing Trials – Lessons Learnt
- Defining clear roles and responsibilities between sponsor and CRO to avoid duplication and gaps
- Identifying what sponsors should actively oversee versus what can be delegated with confidence
- Setting oversight models that focus on risk rather than excessive monitoring
- Improving communication and escalation pathways to prevent delays and misalignment